Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Eden vs JRNYS

Eden
Site position #16

Higher grade

JRNYS
Site position #302

Lower grade

The verdict

Eden takes it — 81.6/100 to 62.5/100.

Eden grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Eden advertises lower-priced compounded bundles, but its offer and linked membership and warranty terms need to be reconciled before purchase.

We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueEden +40
85
45
Dose & formulationEden +28
86
58
Clinical oversightJRNYS +29
55
84
Labs & monitoringEden +21
92
71
FulfillmentEden +28
93
65
Contract termsEden +35
90
55
Eden · top barJRNYS · bottom bar

The numbers

Swipe or scroll to compare both providers.

MetricEdenJRNYS
WeighScore81.6/10062.5/100
GradeB−C
Site position#16#302
SemaglutideAdvertised $99/mo bundle; linked membership terms conflict—confirm checkoutNot disclosed
TirzepatideAdvertised $129/mo bundle; linked membership terms conflict—confirm checkoutNot disclosed
CoverageAll 50 statesCoverage not published
Brand-name accessYesYes
Oral / sublingualNot confirmedNot confirmed
Eden

Site position #16 · B−

FDAWarning letter issued to Eden Health International Inc. dba Eden in June 2026. See the FDA warning-letter database.

Strengths

  • Current compounded offer includes medication and support
  • Homepage also advertises branded prescription pathways; eligibility and cost require confirmation
  • Named pharmacy operation and partner network can be investigated

What to consider

  • Linked membership terms describe a separate fee model
  • Landing-page warranty and terms use different thresholds and conditions
  • FDA warning history remains relevant; a new offer does not establish resolution
JRNYS

Site position #302 · C

Strengths

  • Branded, FDA-approved GLP-1s — Wegovy, Ozempic, Zepbound, Mounjaro and Saxenda — rather than compounded copies
  • The membership band is published before intake and is banded openly by level of coach support
  • Medical visits, daily monitoring and 1-on-1 coaching are included in the membership at every tier
  • Led by CMO Dr. Henry Legere (UC Berkeley, Columbia medicine, Harvard fellowship)
  • Members with commercial insurance may pay around $25 a month for the medication after any deductible

What to consider

  • The membership is overhead, not a medication price: it covers visits, monitoring and coaching, and the FAQ says medication pricing is confirmed only after a provider consultation
  • No self-pay drug price is published anywhere, so the cost of a month cannot be worked out before signing up
  • The best case depends on commercial insurance coverage; without it the medication cost is unknown
  • No compounded option is disclosed — the program is brand-focused, and brand list prices are the dearest route to a GLP-1
  • The states it can prescribe in are not published

Featured provider

Eden

Eden scores 81.6/100 (B−). Eden advertises lower-priced compounded bundles, but its offer and linked membership and warranty terms need to be reconciled before purchase.

Commercial relationships affect this placement. The score comparison above is separate.

FDAWarning letter issued to Eden Health International Inc. dba Eden in June 2026. See the FDA warning-letter database.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard